Today we announced that Health Canada has authorized our updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. We are on track to deliver the updated vaccine in time for the 2025-2026 vaccination season.

Earlier today, Moderna reported financial results and provided business updates for the second quarter of 2025. Members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones. Watch now:

Today, we reported financial results and provided business updates for the second quarter of 2025. Read more:

Today we announced that the UK Court of Appeal has upheld the validity of our EP’949 patent. Read more:

Today we announced that the European Commission has granted marketing authorization for the updated formulation of our COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months

Today we announced that three abstracts on our investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025, in Berlin, Germany. Read more:

Today we announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19  vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for

For Jagjit Ludu, joining Moderna meant the chance to think differently and connect science to people in new ways. From launching clinician-focused docu-series to building AI-powered tools for bite-sized learning, he’s reshaping how Medical Affairs engages and informs. 💡 “Being

We are proud to share the results of our mRNA-1283 Phase 3 trial in @TheLancetInfDis. Read more:

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax®, our COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. Our COVID-19 vaccine,

Today we announced positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy against influenza illness of mRNA-1010, our seasonal influenza vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and

We announced today that the U.S. FDA has approved mRESVIA®, our respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 18–59 years of age who are at increased risk for disease. This approval expands the

mNEXSPIKE® (COVID-19 vaccine, mRNA) is now approved in the U.S., marking our third approved product. We are proud of our platform’s continued impact, and our relentless commitment to excellence. Read more from our CEO Stéphane Bancel about this approval, and what’s next:

We announced today that the U.S. FDA has approved mNEXSPIKE®, a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes

Today we announced an update on our investigational pandemic influenza program. Learn more:

Today we announced that we have submitted an application to the U.S. Food and Drug Administration for review of our Spikevax 2025-2026 formula, a COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1. Read more:

Today we announced an update on our BLA submission for our combination vaccine against influenza and COVID-19. Read more:

Today, on #ClinicalTrialsDay, we pause to thank the people who make progress in medicine possible. To the participants who lend their time, trust and courage. To the researchers who push the boundaries of science. To the coordinators, nurses and support staff who keep it all